Showing 3951-3960 of 9345 results for "".
- Emerging Technologies, Consumer Preferences Drive Microdermabrasion Market Expansionhttps://practicaldermatology.com/news/emerging-technologies-and-consumer-preferences-drive-microdermabrasion-market-expansion/2466901/A new market report indicates that microdermabrasion devices are increasingly favored in the treatment of conditions like acne, acne scars, fine lines, and wrinkles, and that the market for these devices is poised for growth. The growth, according to the report from Coherent Market Insig
- Study: Markers Reveal New Diagnostic Paths in Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/study-markers-reveal-new-diagnostic-paths-chronic-spontaneous-urticaria/2462978/A recent study highlighted new diagnostic markers and pathways in chronic spontaneous urticaria (CSU). Researchers publishing in the International Journal of Dermatology included 90 CSU patients and 90 healthy individuals in the analysis. The authors then analyzed markers from di
- Survey: More than Half of Americans Seek Skin Care and Other Products Aligned with Sustainable Lifestyleshttps://practicaldermatology.com/news/survey-more-half-americans-seek-skin-care-and-other-products-aligned-sustainable-lifestyles/2462882/A recent consumer sentiment survey showed that over half of Americans are inclined to try new products (including those for skin care) marketed as aligned with healthier and more sustainable lifestyles. The survey
- UCB Receives European Approval for Hidradenitis Suppurativa Treatment Bimzelxhttps://practicaldermatology.com/news/ucb-receives-european-approval-hidradenitis-suppurativa-treatment-bimzelx/2462815/The European Commission has granted marketing authorization for UCB’s Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy.1 Bimzelx is the first IL-17A and IL-17F bi
- Cosmeceutical Market Continues Strong Rise, May Double by 2030https://practicaldermatology.com/news/cosmeceutical-market-continues-strong-rise-may-double-2030/2462662/Advances in technology, an aging population, and increasing interest in natural and organic products are among the trends driving growth in the global cosmeceutical market, according to data from a recent consumer report from SNS Insider, a market research company. The global cosmeceutica
- FDA Gives Nod to Marketing DermaSensor for Skin Lesion Evaluationhttps://practicaldermatology.com/news/fda-gives-nod-to-dermasensor-for-skin-lesion-evaluation/2462213/The U.S Food and Drug Administration (FDA) announced that it has granted authorization for marketing for the DermaSensor (DermaSensor Inc.) prescription device, indicated for the evaluation of skin lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma in patients ag
- FDA Clears Sofwave’s SUPERB Technology for Treating Acne Scarshttps://practicaldermatology.com/news/fda-clears-sofwaves-superb-technology-for-treating-acne-scars/2461969/The U.S. Food and Drug Administration (FDA) has cleared Sofwave’s SUPERB technology for treating acne scars. “Gaining FDA clearance to market SUPERB for the treatment of acne scarring not only paves the way to positively impact patients seeking improved appearances
- Unpacking the AAD’s Updated Guidelines for Managing AD With Topical Therapies in Adultshttps://practicaldermatology.com/news/guideline-author-dr-robert-sidbury-talks-to-dermwire-about-the-new-recommendations/2461953/Despite the availability of systemic medication to treat atopic dermatitis (AD), topical treatments remain mainstays, and new ones have come to market in recent years. To keep pace with the changes, the American Academy of Dermatology (AAD) updated its 2014 guidelines for managing atopi
- EMA Accepts LEO Pharma’s MAA for Delgocitinib Cream in Chronic Hand Eczemahttps://practicaldermatology.com/news/ema-accepts-leo-pharmas-maa-for-delgocitinib-cream-in-chronic-hand-eczema/2461942/The European Medicines Agency (EMA) has validated LEO Pharma’s marketing authorization application for delgocitinib cream, an investigational product and topical pan-Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe chronic hand eczema (CHE).
- Azitra Adds Barbara Ryan and John Schroer to Board of Directorshttps://practicaldermatology.com/news/azitra-adds-barbara-ryan-and-john-schroer-to-board-of-directors/2461876/Barbara Ryan and John Schroer joined Azitra, Inc.’s board of directors. "We are thrilled to further strengthen the Azitra team by welcoming Barbara and John to our board and by leveraging their wealth of knowledge in biotech, corporate strategy, and capital markets,